Acute myeloid leukemia-driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias

Haematologica. 2024 May 1;109(5):1576-1581. doi: 10.3324/haematol.2023.283944.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic* / pharmacology
  • Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
  • Cytopenia
  • Hematopoietic Stem Cells* / drug effects
  • Hematopoietic Stem Cells* / metabolism
  • Humans
  • Interleukin-3* / metabolism
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / metabolism
  • Leukemia, Myeloid, Acute* / pathology
  • Proto-Oncogene Proteins c-bcl-2* / genetics
  • Proto-Oncogene Proteins c-bcl-2* / metabolism
  • Sulfonamides* / pharmacology
  • Up-Regulation / drug effects

Substances

  • Antineoplastic Agents
  • BCL2 protein, human
  • Bridged Bicyclo Compounds, Heterocyclic
  • IL3 protein, human
  • Interleukin-3
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • venetoclax